Clinical trials: Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus Infections
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers
This study will assess the safety, tolerability, and pharmacokinetics (PK) of orally administered ALS-008176 in healthy volunteers.
- Trial name
- NCT01906164
- Testing
- ALS-008176
- Where
- France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the…
- Trial name
- NCT07220109
- Testing
- RSVPreF3 OA vaccine
- Where
- 15 sites in China
- Volunteers
- 750 people
- Sponsor
- GlaxoSmithKline
SARS-CoV2 Infection, Influenza A
Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of: 1. ClariLight Influenza A/B \& SARS-CoV-2 test kits and 2.
- Conditions
- SARS-CoV2 Infection, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT06175611
- Testing
- COVID-19/Flu A/Flu B/RSV Test Kit
- Where
- 3 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- EDAN Instruments Inc.
Respiratory Synctial Virus Infections
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults
The purpose of this first time in human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of 2 doses of the RSV investigational vaccine, when administered intramuscularly according to a 0, 1 month schedule…
- Trial name
- NCT02491463
- Testing
- GSK3389245A_LD GROUP, GSK3389245A_HD GROUP, Bexsero
- Where
- United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV)
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised…
- Trial name
- NCT07768345
- Testing
- RSVpreF Vaccine
- Where
- 17 sites in United States
- Volunteers
- 440 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies.
- Trial name
- Amélie (NCT06473519)
- Testing
- RSVpreF MDV, RSVpreF SDV
- Where
- 6 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of two doses of the investigational RSV F subunit vaccine administered intramuscularly (IM).
- Trial name
- NCT02298179
- Testing
- RSV F subunit 45 μg No adjuvant, RSV F subunit 45 μg Aluminum hydroxide adjuvant, RSV F subunit 45 μg MF59 adjuvant
- Where
- Belgium
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and…
- Trial name
- NCT04886596
- Testing
- RSVPreF3 OA vaccine
- Where
- 277 sites in United States, Australia and 15 more
- Volunteers
- 26,675 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections, Virus Diseases
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to evaluate pharmacokinetics, safety, tolerability, antiviral activity, and impact on the clinical course of Respiratory Syncytial Virus (RSV) infection after multiple oral doses of JNJ-53718678 at…
- Trial name
- NCT02593851
- Testing
- JNJ-53718678
- Where
- 39 sites in United States, Argentina and 8 more
- Volunteers
- 45 people
- Sponsor
- Janssen Sciences Ireland UC
Respiratory Syncytial Virus Infections
Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults
The main aims of the study are to assess the safety, tolerability, pharmacokinetics and food effects of RV299 compared to Placebo in healthy adult participants.
- Trial name
- NCT06033612
- Testing
- RV299, Midazolam
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV)…
- Conditions
- Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection
- Trial name
- NCT04933968
- Testing
- ALVR106
- Where
- 21 sites in United States
- Volunteers
- 17 people
- Sponsor
- AlloVir
Respiratory Syncytial Virus
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm…
- Trial name
- MEDI8897 1b (NCT02290340)
- Testing
- MEDI8897 10 mg, MEDI8897 25 mg, MEDI8897 50 mg
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection
A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
This is a randomized, observer-blinded, placebo-controlled Phase III clinical trial to evaluate efficacy, immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
- Conditions
- Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection, RSV Vaccine
- Trial name
- NCT07908654
- Testing
- LYB005
- Where
- China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Healthy
An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults
The purpose of this study is to assess a trend for the prophylactic efficacy of a single dose of 1*10^11 virus particles (vp) of adenovirus serotype 26 respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) administered…
- Trial name
- NCT03334695
- Testing
- Ad26.RSV.preF
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
RSV Infection, hMPV
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
- Trial name
- NCT06583031
- Testing
- RSV/hMPV vaccine dose A1, RSV/hMPV vaccine dose A2, RSV/hMPV vaccine dose A3
- Where
- 6 sites in Australia
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infection Prevention
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared…
- Trial name
- NCT05070546
- Testing
- Ad26.RSV.preF-based Vaccine
- Where
- 23 sites in United States, Belgium and 3 more
- Volunteers
- 1,124 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
RSV Infection
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b.
- Trial name
- NCT03691623
- Testing
- EDP-938 Dose 1, EDP-938 Dose 2, EDP-938 Dose 3
- Where
- United Kingdom
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus Infections
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose.
- Trial name
- NCT04227210
- Testing
- RSV vaccine MV-012-968 (dosage #1), RSV vaccine MV-012-968 (dosage #2)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Meissa Vaccines, Inc.
Respiratory Syncytial Virus Infections
Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers
The study is a multi-center, multi-national, prospective surveillance study in which the study participants will not receive a study vaccine but will provide a baseline blood sample and be followed for acute respiratory disease…
- Trial name
- NCT05964582
- Where
- 15 sites in United States, Finland and 5 more
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant…
- Trial name
- NCT02247726
- Testing
- RSV F vaccine (0.5mL injection)
- Where
- 7 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novavax